Center for Molecular Medicine Cologne

Schommers, Philipp - assoc. JRG 07 and CAP 26

Laboratory of Antiviral Immunity

Introduction

Interactions between viruses and the immune system of an infected patient have a strong influence on both organisms. After infection, the human immune system aims to improve its ability to detect and combat the respective virus while the pathogen can develop escape mutations that allow him to evade these immune responses. If these mutations also do not alter the ‘viral fitness’ (its ability to replicate and infect more cells), this viral quasispecies will have an evolutionary advantage over the ancestral virus, will finally outnumber him and force the human immune system to adapt its response again.
With the overall aim to improve future antiviral therapies and vaccines, our group aims to i) better understand these host-virus interactions, ii) implement novel techniques to rapidly detect viral escape and iii) develop strategies that hamper viral escape.

Current Projects

One of the most prominent examples of viral escape in the recent years has been SARS-CoV-2 of which new variants have acquired more and more escape mutations that led to a significantly hampered detection and neutralization of the virus by the humoral immune system and monoclonal antibodies. However, while viruses like SARS-CoV-2 that result in an acute infection only rarely develop escape mutations in most patients, chronically infecting viruses like HIV-1 can develop numerous escape mutations in a single patient over the years which leads to a co-evolution of the immune system and the virus. In very few patients, this co-evolution leads to the development of broadly neutralizing antibodies (bNAbs) that can neutralize up to 100% of worldwide circulating strains. Antibodies have been ground-breaking in the therapy of autoimmune diseases and cancer and with the recent identification of new highly potent bNAbs, antibodies will also play a key role in future HIV-1 treatment and prevention strategies. HIV-1 reactive bNAbs that target different epitopes on the envelope trimer (Figure 1) have been tested in many clinical studies in recent years, where they demonstrated safe suppression of viremia, a delay of viral rebound after interruption of ART and protection of humans against sensitive strains. The characterization of the interplay between bNAbs and the HIV-1 envelope protein also significantly facilitated the design of novel HIV-1 vaccines of which several candidates are currently already being evaluated in clinical studies.

Figure 1

Current Challenges

As for any drug against HIV-1, viral resistance and escape represent formidable challenges for currently available bNAbs. Effective bNAb therapies and vaccines could be hampered by de novo and pre-existing HIV-1 antibody resistances (HIVAR). RNA viruses, like HIV-1, are characterized by exceptionally high rates of spontaneous mutation. Especially the HIV-1 envelope protein (HIVenv) can rapidly evade the immune pressure mediated by neutralizing antibodies and clinical trials have shown that such mutations pre-exist in many patients and/or can develop quickly de novo during treatment with bNAbs in humans. Moreover, HIV-1 vaccines that are designed to elicit bNAbs in vaccinees can only be protective against sensitive strains. Thus, rapid testing of patients or even large cohorts for their bNAb sensitivity is crucial for future clinical use of bNAbs of bNAb-inducing vaccines (Figure 2).

Figure 2

Our aims and further perspectives

Our group aims to develop novel methods that will allow the rapid identification of HIV-1 antibody resistances (HIVAR) from replication or translationally competent proviruses in HIV-1 infected individuals (Figure 3). This will help to further characterize and understand HIVAR which will be of upmost importance for future clinical studies. As a result, our work will significantly help to improve future bNAb treatment and prevention strategies as well as HIV-1 vaccines that elicit bNAbs and has the capability to significantly improve the life of HIV-1-infected patients.

Figure 3

  • Schommers P*, Gruell H*, Abernathy ME*, Tran MK, Dingens AS, Gristick HB, Barnes CO, Schoofs T, Schlotz M, Vanshylla K, Kreer C, Weiland D, Holtick U, Scheid C, Valter MM, van Gils MJ, Sanders RW, Vehreschild JJ, Cornely OA, Lehmann C, Fätkenheuer G, Seaman MS, Bloom JD, Bjorkman PJ, Klein F. Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody. Cell (2020); 180(3):471-489
  • Gruell H, Schommers P. Broadly neutralizing antibodies against HIV-1 and concepts for application. Current Opinion in Virology (2022); 54, 101211.
  • Warnat-Herresthal S*, Schultze H*, Shastry KL*, Manamohan S*, Mukherjee S*, Garg V*, Sarveswara R*, Händler K*, Pickkers P*, Aziz NA*, Ktena S*, Tran F, Bitzer M, Ossowski S, Casadei N, Herr C, Petersheim D, Behrends U, Kern F, Fehlmann T, Schommers P, Lehmann C, Augustin M, Rybniker J, et al. Swarm Learning for decentralized and confidential clinical machine learning. Nature (2021); 594(7862):265-270
  • COVID-19 Host Genetics Initiative. Mapping the human genetic architecture of COVID-19. Nature 2021; 600(7889):472-477
  • Kreer C*, Zehner M*, Weber T, Ercanoglu MS, Gieselmann L, Rohde C, Halwe S, Korenkov M, Schommers P, Vanshylla K, Di Cristanziano V, Janicki H, Brinker R, Ashurov A, Krähling V, Kupke A, Cohen-Dvashi H, Koch M, Eckert JM, Lederer S, Pfeifer N, Wolf T, Vehreschild MJGT, Wendtner C, Diskin R, Gruell H, Becker S, Klein F. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell (2020); 182(4):843-854
  • Gruell H, Vanshylla K, Tober-Lau P, Hillus D, Schommers P, Lehmann C, Kurth F, Sander LE, Klein F. mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omi-cron variant. Nature Medicine (2022); Jan 19:1-4
  • Schoofs T*, Barnes CO*, Suh-Toma N, Golijanin J, Schommers P, Gruell H, West AP Jr, Bach F, Lee YE, Nogueira L, Georgiev IS, Bailer RT, Czartoski J, Mascola JR, Seaman MS, McElrath MJ, Doria-Rose NA, Klein F, Nussenzweig MC, Bjorkman PJ. Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope. Immunity (2019); 50(6):1513-1529
  • Gruell H, Vanshylla K, Korenkov M, Tober-Lau P, Zehner M, Münn F, Janicki H, Augustin M, Schommers P, Sander LE, Kurth F, Kreer C, Klein F. SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns. (Cell Host Microbe, 2022)
  • Degenhardt F, Ellinghaus D, Juzenas S,…, Schommers P,…, Karlsen TH, Cáceres M, Franke A. Detailed stratified GWAS analysis for severe COVID-19 in four European populations. (Human Molecular Genetics, 2022)
  • Bannister WP, Mast TC, de Wit S, Gerstoft J, Wiese L, Milinkovic A, Hadziosmanovic V, Clarke A, Rasmussen LD, Lacombe K, Schommers P, Staub T, Zagalo A, Portu JJ, Tau L, Calmy A, Cavassini M, Gisinger M, Borodulina E, Mocroft A, Reekie J, Peters L; EuroSIDA study group. Changes in body mass index and clinical outcomes after initiation of contemporary antiretroviral regimens (AIDS, 2022)
  • Weber S, Kehl V, Erber J, Wagner KI, Jetzlsperger AM, Burrell T, Schober K, Schommers P, Augustin M, Crowell CS, Gerhard M, Winter C, Moosmann A, Spinner CD, Protzer U, Hoffmann D, D'Ippolito E, Busch DH. CMV seropositivity is a potential novel risk factor for severe COVID-19 in non-geriatric patients. (PloS One, 2022)
  • Tober-Lau P, Gruell H, Vanshylla K, Koch WM, Hillus D, Schommers P, Suárez I, Suttorp N, Sander LE, Klein F, Kurth F. Cross-Variant Neutralizing Serum Activity after SARS-CoV-2 Breakthrough Infections. (Emerging Infectious Diseases, 2022)
  • Gruell H, Vanshylla K, Tober-Lau P, Hillus D, Schommers P, Lehmann C, Kurth F, Sander LE, Klein F. mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omi-cron variant. (Nature Medicine, 2022)
  • Vanshylla K, Fan C, Wunsch M, Poopalasingam N, Meijers M, Kreer C, Kleipass F, Ruchnewitz D, Ercanoglu MS, Gruell H, Münn F, Pohl K, Janicki H, Nolden T, Bartl S, Stein SC, Augustin M, Dewald F, Gieselmann L, SchommersP, Schulz TF, Sander LE, Koch M, Łuksza M, Lässig M, Bjorkman PJ, Klein F. Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers. (Cell Host Microbe, 2022)
  • Gruell H, Schommers P. Broadly neutralizing antibodies against HIV-1 and concepts for application. (Current Opinion in Virology, 2022)
  • Wagh K, van Gils MJ, Gristick H, Schommers P. Editorial: Novel Concepts in Using Broadly Neutralizing Antibodies for HIV-1 Treatment and Prevention. (Frontiers in Immunology, 2021)
  • Augustin M *, Schommers P*, Stecher M*, Dewald F, Gieselmann L, Gruell H, Horn C, Vanshylla K, Cristanziano VD, Osebold L, Roventa M, Riaz T, Tschernoster N, Altmueller J, Rose L, Salomon S, Priesner V, Luers JC, Albus C, Rosenkranz S, Gathof B, Fätkenheuer G, Hallek M, Klein F, Suárez I, Lehmann C. Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective co-hort study. (Lancet Regional Health Europe, 2021)
  • Hentrich M, Müller M, Wyen C, Bogner J, Thomssen H, Wasmuth JC, Wolf T, Hoffmann C*, Schommers P*. Characteristics and outcome of human immunodeficiency virus (HIV)-associated primary effusion lymphoma as observed in the German HIV-related lymphoma cohort study. (British Journal of Haematology, 2021)
  • Nakanishi T, Pigazzini S, Degenhardt F, Cordioli M, Butler-Laporte G, Maya-Miles D, Bujanda L, Bouysran Y, Niemi ME, Palom A, Ellinghaus D, Khan A, Martínez-Bueno M, Rolker S, Amitrano S, Roade Tato L, Fava F; FinnGen; COVID-19 Host Genetics Initiative (HGI), Spinner CD, Prati D, Bernardo D, Garcia F, Darcis G, Fernández-Cadenas I, Holter JC, Banales JM, Frithiof R, Kiryluk K, Duga S, Asselta R, Pereira AC, Romero-Gómez M, Nafría-Jiménez B, Hov JR, Migeotte I, Renieri A, Planas AM, Ludwig KU, Buti M, Rahmouni S, Alarcón-Riquelme ME, Schulte EC, Franke A, Karlsen TH, Valenti L, Zeberg H, Richards JB, Ganna A. Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality. (Journal of Clinical Investigation, 2021)
  • COVID-19 Host Genetics Initiative. Mapping the human genetic architecture of COVID-19. (Nature, 2021)
  • Warnat-Herresthal S*, Schultze H*, Shastry KL*, Manamohan S*, Mukherjee S*, Garg V*, Sarveswara R*, Händler K*, Pickkers P*, Aziz NA*, Ktena S*, Tran F, Bitzer M, Ossowski S, Casadei N, Herr C, Petersheim D, Behrends U, Kern F, Fehlmann T, Schommers P, Lehmann C, Augustin M, Rybniker J, Altmüller J, Mishra N, Bernardes JP, Krämer B, Bonaguro L, Schulte-Schrepping J, De Domenico E, Siever C, Kraut M, Desai M, Monnet B, Saridaki M, Siegel CM, Drews A, Nuesch-Germano M, Theis H, Heyckendorf J, Schreiber S, Kim-Hellmuth S; COVID-19 Aachen Study (CO-VAS), Nattermann J, Skowasch D, Kurth I, Keller A, Bals R, Nürnberg P, Rieß O, Rosenstiel P, Netea MG, Theis F, Mukherjee S, Backes M, Aschenbrenner AC, Ulas T; Deutsche COVID-19 Omics Initia-tive (DeCOI), Breteler MMB, Giamarellos-Bourboulis EJ, Kox M, Becker M, Cheran S, Woodacre MS, Goh EL, Schultze JL. Swarm Learning for decentralized and confidential clinical machine learning. (Nature, 2021)
  • Gieselmann L*, Kreer C*, Ercanoglu MS, Lehnen N, Zehner M, Schommers P, Potthoff J, Gruell H, Klein F. Effective high-throughput isolation of fully human antibodies targeting infectious pathogens. (Nature Protocols, 2021)
  • Vanshylla K, Di Cristanziano V, Kleipass F, Dewald F, Schommers P, Gieselmann L, Gruell H, Schlotz M, Ercanoglu MS, Stumpf R, Mayer P, Zehner M, Heger E, Johannis W, Horn C, Suárez I, Jung N, Salomon S, Eberhardt KA, Gathof B, Fätkenheuer G, Pfeifer N, Eggeling R, Augustin M, Lehmann C, Klein F. Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans. (Cell Host Microbe, 2021)
  • Eberhardt KA, Dewald F, Heger E, Gieselmann L, Vanshylla K, Wirtz M, Kleipass F, Johannis W, Schommers P, Gruell H, Brensing KA, Müller RU, Augustin M, Lehmann C, Koch M, Klein F, Di Cristanziano V. Evaluation of a New Spike (S)-Protein-Based Commercial Immunoassay for the Detection of Anti-SARS-CoV-2 IgG. (Microorganisms, 2021)
  • Stecher M*, Schommers P*, Kollan C, Stoll M, Kuhlendahl F, Stellbrink HJ, Wasmuth JC, Stephan C, Hamacher L, Lehmann C, Boesecke C, Bogner J, Esser S, Fritzsche C, Haberl A, Hoffmann C, Jensen B, Schwarze-Zander C, Platten M, Fätkenheuer G, Schmidt D, Gunsenheimer-Bartmeyer B, Vehreschild JJ; ClinSurv Study Group.Treatment modification after starting cART in people living with HIV: retrospective analysis of the German ClinSurv HIV Cohort 2005-2017. (Infection, 2020)
     
  • Augustin M*, Schommers P*, Suárez I*, Koehler P, Gruell H, Klein F, Maurer C, Langerbeins P, Priesner V, Schmidt-Hellerau K, Malin JJ, Stecher M, Jung N, Wiesmüller G, Meissner A, Zweigner J, Langebartels G, Kolibay F, Suárez V, Burst V, Valentin P, Schedler D, Cornely OA, Hallek M, Fätkenheuer G, Rybniker J, Lehmann C. Rapid response infrastructure for pandemic preparedness in a tertiary care hospital: lessons learned from the COVID-19 outbreak in Cologne, Germany, February to March 2020. (Euro Surveillance, 2020)
  • Schommers P*, Gruell H*, Abernathy ME*, Tran MK, Dingens AS, Gristick HB, Barnes CO, Schoofs T, Schlotz M, Vanshylla K, Kreer C, Weiland D, Holtick U, Scheid C, Valter MM, van Gils MJ, Sanders RW, Vehreschild JJ, Cornely OA, Lehmann C, Fätkenheuer G, Seaman MS, Bloom JD, Bjorkman PJ, Klein F. Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody. (Cell, 2020)
  • Eberhardt KA*, Meyer-Schwickerath C*, Heger E, Knops E, Lehmann C, Rybniker J, Schommers P, Eichenauer DA, Kurth F, Ramharter M, Kaiser R, Holtick U, Klein F, Jung N, Di Cristanziano V. RNAemia Corresponds to Disease Severity and Antibody Response in Hospitalized COVID-19 Patients. (Viruses, 2020)
  • Kreer C*, Zehner M*, Weber T, Ercanoglu MS, Gieselmann L, Rohde C, Halwe S, Korenkov M, Schommers P, Vanshylla K, Di Cristanziano V, Janicki H, Brinker R, Ashurov A, Krähling V, Kupke A, Cohen-Dvashi H, Koch M, Eckert JM, Lederer S, Pfeifer N, Wolf T, Vehreschild MJGT, Wendtner C, Diskin R, Gruell H, Becker S, Klein F. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. (Cell, 2020)
  • Kreer C*, Döring M*, Lehnen N, Ercanoglu MS, Gieselmann L, Luca D, Jain K, Schommers P, Pfeifer N, Klein F. openPrimeR for multiplex amplification of highly diverse templates. (Journal of Immunological Methods, 2020)
  • Ehrhardt SA*, Zehner M*, Krähling V, Cohen-Dvashi H, Kreer C, Elad N, Gruell H, Ercanoglu MS, Schommers P, Gieselmann L, Eggeling R, Dahlke C, Wolf T, Pfeifer N, Addo MM, Diskin R, Becker S, Klein F. Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV. (Nature Medicine, 2019)
  • Schleimann MH, Kobberø ML, Vibholm LK, Kjær K, Giron LB, Busman-Sahay K, Chan CN, Nekorchuk M, Schmidt M, Wittig B, Damsgaard TE, Ahlburg P, Hellfritzsch MB, Zuwala K, Rothemejer FH, Olesen R, Schommers P, Klein F, Dweep H, Kossenkov A, Nyengaard JR, Estes JD, Abdel-Mohsen M, Østergaard L, Tolstrup M, Søgaard OS, Denton PW. TLR9 agonist MGN1703 enhances B cell differentiation and function in lymph nodes. (EBioMedicine 2019)
  • Schoofs T*, Barnes CO*, Suh-Toma N, Golijanin J, Schommers P, Gruell H, West AP Jr, Bach F, Lee YE, Nogueira L, Georgiev IS, Bailer RT, Czartoski J, Mascola JR, Seaman MS, McElrath MJ, Doria-Rose NA, Klein F, Nussenzweig MC, Bjorkman PJ. Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope. (Immunity, 2019)
  • Schommers P*, Gillor D*, Hentrich M, Wyen C, Wolf T, Oette M, Zoufaly A, Wasmuth JC, Bogner JR, Müller M, Esser S, Schleicher A, Jensen B, Stoehr A, Behrens G, Schultze A, Siehl J, Thoden J, Taylor N, Hoffmann C. Incidence and risk factors for relapses in HIV-associated non-Hodgkin lymphoma as observed in the German HIV-related lymphoma cohort study. (Haematologica, 2018)
  • Stecher M, Schommers P, Schmidt D, Kollan C, Gunsenheimer-Bartmeyer B, Lehmann C, Platten M, Fätkenheuer G, Vehreschild JJ; ClinSurv Study Group. Antiretroviral treatment indications and adherence to the German-Austrian treatment initiation guidelines in the German ClinSurv HIV Cohort between 1999 and 2016. (Infection, 2018)
  • Hughes RA, May MT, Tilling K, Taylor N, Wittkop L, Reiss P, Gill J, Schommers P, Costagliola D, Guest JL, Lima VD, Monforte AD, Smith C, Cavassini M, Saag M, Sterling TR, Sterne JAC. Longterm trends in CD4 cell counts, CD8 cell counts, and the CD4: CD8 ratio: ART Cohort Collaboration (ART-CC) Study. (AIDS, 2018)
  • Schommers P*, Thurau A*, Bultmann-Mellin I*, Guschlbauer M, Klatt AR, Rozman J,Klingenspor M, de Angelis MH, Alber J, Gründemann D, Sterner-Kock A, Wiesner RJ. Metformin causes a futile in-testinal-hepatic cycle which increases energy expenditure and slows down development of a type 2 diabetes-like state. (Molecular Metabolism, 2017)
  • Trickey A, May MT, Schommers P, Tate J, Ingle SM, Guest JL, Gill MJ, Zangerle R, Saag M, Reiss P, Monforte AD, Johnson M, Lima VD, Sterling TR, Cavassini M,Wittkop L, Costagliola D, Sterne JAC; Antiretroviral Therapy Cohort Collaboration(ART-CC). CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus-Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC). (ClinicalInfectious Diseases, 2017)
  • Körner C, Simoneau CR, Schommers P, Granoff M, Ziegler M, Hölzemer A, Lunemann S, Chukwukelu J, Corleis B, Naranbhai V, Kwon DS, Scully EP, Jost S, Kirchhoff F,Carrington M, Altfeld M. HIV-1-Mediated Downmodulation of HLA-C Impacts Target Cell Recognition and Antiviral Activi-ty of NK Cells. (Cell Host & Microbe, 2017)
  • Schommers, P, Martrus, G, Matschl, U, Sirignano, M, Lütgehetmann, M, Richert, L, Hope, TJ, Fätkenheuer, G, Altfeld, M. Changes in HIV-1 Capsid stability induced by common CTL-driven viral sequence mutations. (Journal of Virology, 2016)
  • Hoffmann C*, Schommers P*, Wolf E, Müller M, Schultze A, Krznaric I, Stoehr A, Wolf T, Fäktenheuer G, Stier B, Wyen C, Hentrich M. CD4+ and CD8+ T-cell kinetics in aviremic HIV-infected patients developing Hodgkin or non-Hodgkin lymphoma. (AIDS, 2016)
  • Wang Q, De Luca A, Smith C, Zangerle R, Sambatakou H, Bonnet F, Smit C, Schommers P, Thornton A, Berenguer J, Peters L, Spagnuolo V, Ammassari A, Antinori A, Roldan EQ, Mussini C, Miro JM, Konopnicki D, Fehr J, Campbell MA, Termote M, Bucher HC; Hepatitis Coinfection and Non Hodgkin Lymphoma project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. Chronic Hepatitis B and C Virus Infection and Risk for Non-Hodgkin Lymphoma in HIV-Infected Patients: A Cohort Study. (Annals of Internal Medicine, 2016)
  • Franko A, Huypens P, Neschen S, Irmler M, Rozman J, Rathkolb B, Neff F, Prehn C, Dubois G, Baumann M, Massinger R, Gradinger D, Przemeck GK, Repp B, Aichler M, Feuchtinger A, Schommers P, Stöhr O, Sanchez-Lasheras C, Adamski J, Peter A, Prokisch H, Beckers J, Walch AK, Fuchs H, Wolf E, Schubert M, Wiesner RJ, Hrabě de Angelis M. Bezafibrate improves insulin sensitivity and metabolic flexibility in STZ-treated diabetic mice. (Diabetes, 2016)
  • Schommers P*, Hentrich M*, Hoffmann C, Gillor D, Zoufaly A, Jensen B, Bogner JR, Thoden J, Wasmuth JC, Wolf T, Oette M, Müller M, Esser S, Fätkenheuer G, Wyen C Survival with AIDS-related diffuse large B-cell lymphoma, Burkitt lymphoma, and plasmablastic lymphoma in the German HIV Lymphoma Cohort. (British Journal of Haematology, 2015)
  • Franko A*, von Kleist-Retzow JC*, Neschen S, Wu M, Schommers P, Böse M, Kunze A, Hartmann U, Sanchez-Lasheras C, Stoehr O, Huntgeburth M, Brodesser S, Irmler M, Beckers J, de Angelis MH, Paulsson M, Schubert M, Wiesner RJ. Liver adapts mitochondrial function to insulin resistant and diabetic states in mice. (Journal of Hepatology, 2014)
  • Xicoy B*, Ribera JM*, Müller M, García O, Hoffmann C, Oriol A, Hentrich M, Grande C, Wasmuth JC, Esteve J, van Lunzen J, Del Potro E, Knechten H, Brunet S,  Mayr C, Escoda L, Schommers P, Alonso N, Vall-Llovera F, Pérez M, Morgades M, González J, Fernández A, Thoden J, Gökbuget N, Hoelzer D, Fätkenheuer G, Wyen C;  for the PETHEMA Group and German HIV Lymphoma Cohort. Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: parallel study of 81 patients. (Leukemia and Lymphoma, 2014)
  • Schommers P*, Wyen C*, Hentrich M, Gillor D, Zoufaly A, Jensen B, Bogner JR,Thoden J, Wasmuth JC, Fätkenheuer G, Hoffmann C. Poor outcome of HIV-infected patients with plasmablastic lymphoma: results from the German AIDS-related lymphoma cohort study. (AIDS, 2013)
  • Re A, Cattaneo C, Skert C, Balsalobre P, Michieli M, Bower M, Ferreri AJ, Hentrich M, Ribera JM, Allione B, Schommers P, Montoto S, Almici C, Ferremi P, Mazzucato M, Gattillo S, Casari S, Spina M, Diez-Martin JL, Tirelli U, Rossi G; Cooperative European Group on AIDS and Tumors. Stem cell mobilization in HIV seropositive patients with lymphoma. (Haematologica, 2013)
PD Dr. Dr. Philipp Schommers CMMC Cologne
PD Dr. Dr. Philipp Schommers

Clinic I of Internal Medicine & Institute of Virology

CMMC - PI - assoc. JRG 07 and CAP 26

+49 221 478 89659

+49 221 478 1427272

Clinic I of Internal Medicine & Institute of Virology

Robert-Koch-Straße 21

50931 Cologne

CMMC Profile Page

Curriculum Vitae (CV)

Publications on PubMed

Publications - Philipp Schommers

Link to PubMed